Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare ConferenceGlobeNewsWire • 11/27/24
Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi SyndromeGlobeNewsWire • 11/26/24
Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024GlobeNewsWire • 11/14/24
Soleno Therapeutics Nears FDA Decision: Strong Buy Targeting PWS Hyperphagia TreatmentsSeeking Alpha • 10/10/24
Recent Price Trend in Soleno Therapeutics (SLNO) is Your Friend, Here's WhyZacks Investment Research • 10/09/24
Soleno Stock Up as FDA Accepts PWS Drug NDA Under Priority ReviewZacks Investment Research • 08/28/24
Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi SyndromeGlobeNewsWire • 08/27/24
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 08/19/24
Soleno Therapeutics Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi SyndromeGlobeNewsWire • 06/28/24
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Soleno Therapeutics, Inc. (NASDAQ: SLNO) and Encourages Long-Term Investors to Contact the FirmAccesswire • 06/11/24
Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024GlobeNewsWire • 05/22/24
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsGlobeNewsWire • 05/09/24
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common StockGlobeNewsWire • 05/03/24
Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi SyndromeGlobeNewsWire • 04/30/24